Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

The invention describes a method of diagnosing an individual as having an increased likelihood of having an autism spectrum disorder and in some instances, selecting a therapy. The invention is related to a system or a kit for performing such a method.

The present disclosure relates to antibody molecules that bind specifically to C-MET and related nucleic acid molecules, vectors and host cells. Also provided are medical uses of such antibody molecules. The claimed anti C-Met antibodies of the present application have been selected by in silico engineering. Some of the antibodies have been generated and further characterized after expression in mammalian expression system

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFC). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

The present invention provides a prophylactic and/or therapeutic agent for ALS containing a Src/c-Abl pathway inhibitor.

Methods for treating neurodegenerative diseases that can include targeting TANK Binding Kinase 1 (TBK1), I kappa B kinase (IKK), Signal Transducer and Activator of Transcription 1 (STAT1), or Janus Kinase 1 or Janus Kinase 2 (Jak1/2).

AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.

It has been found that canine ECPKA protein secrets in a high level and an autoantibody against the canine ECPKA protein is formed in dogs with cancer. It is also found that human ECPKA does not selectively bind to a canine ECPKA autoantibody and cannot serve as a biomarker. In addition, canine ECPKA autoantibody detection can be used as a meaningful diagnosis tool for cancer in dogs only when quantitative measurement of such antibodies is adapted. When the measurement of canine ECPKA autoantibody is not conclusive, measuring CRP can provide supplemental data that can be used to improve the predictability of the canine ECPKA autoantibody measurement.

The present invention relates to a method for detecting or quantifying ATP in a sample by using a blood glucose meter, the method including adding a sample to be detected to an ATP detection composition containing glucose and an enzyme involved in ATP regeneration so as to convert glucose into glucose-6-phosphate, and then measuring the glucose concentration by using a glucose meter, thereby detecting or quantifying ATP.

The present invention relates to the serine threonine kinase 32C (STK32C) gene relevant to breast cancer and a use thereof, and particularly, to a composition for the diagnosis, prevention, or treatment of breast cancer using the STK32C gene. In the present invention, changes in breast cancer cells according to STK32C gene expression differences were identified, and a breast cancer inhibitory effect according to the inhibition of expression of the STK32C gene and YB-1, which is a substrate protein, were newly verified, and thus target therapies are expected in treatment of breast cancer through more fundamental approaches.